SU5416 (Semaxanib): Selective VEGFR2 Tyrosine Kinase Inhibitor for Angiogenesis and Immune Modulation

Executive Summary: SU5416 (Semaxanib) is a highly selective small molecule inhibitor targeting VEGFR2 (Flk-1/KDR), blocking VEGF-driven angiogenesis in vitro and in vivo (Lemay et al., 2025, https://doi.org/10.1016/j.xcrm.2025.101964). It achieves low-nanomolar IC50 values against VEGFR2-mediated mitogenesis in human endothelial cells. SU5416 is also an agonist of the aryl hydrocarbon receptor (AHR), inducing IDO expression and regulatory T cell differentiation for immunomodulation (APExBIO, product page). The compound is insoluble in water and ethanol but dissolves efficiently in DMSO (≥11.9 mg/mL), with high stability at -20°C. Preclinical studies demonstrate tumor growth suppression and vascular remodeling attenuation in xenograft and pulmonary hypertension models, with a favorable safety profile at active doses. These distinct properties make SU5416 a cornerstone in cancer, angiogenesis, and immunology research.

Biological Rationale

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is essential for tumor growth, metastasis, and tissue regeneration. Vascular endothelial growth factor (VEGF) and its primary receptor VEGFR2 (also known as Flk-1/KDR) are central regulators of endothelial proliferation and neovascularization. Overactivation of VEGFR2 signaling is implicated in cancer, pulmonary arterial hypertension (PAH), and other vascular pathologies (Lemay et al., 2025). Pharmacological inhibition of VEGFR2 restricts angiogenesis, limiting tumor expansion and abnormal vascular remodeling. SU5416 (Semaxanib) was developed as a selective VEGFR2 tyrosine kinase inhibitor to precisely target these pathways. Additionally, SU5416's activity as an AHR agonist introduces an immune-modulatory axis relevant for cancer immunotherapy and autoimmune research (see related analysis).

Mechanism of Action of SU5416 (Semaxanib) VEGFR2 inhibitor

SU5416 competitively inhibits the ATP-binding site of VEGFR2 (Flk-1/KDR) tyrosine kinase. This blocks VEGF-induced phosphorylation events, halting downstream signaling cascades responsible for endothelial cell proliferation, migration, and survival. Inhibition of VEGFR2 suppresses angiogenesis in both physiological and pathological contexts. The compound demonstrates an IC50 of 0.04 ± 0.02 μM for VEGF-driven mitogenesis in HUVEC (human umbilical vein endothelial cells) assays (APExBIO A3847). Beyond anti-angiogenic action, SU5416 is a ligand for the aryl hydrocarbon receptor (AHR), leading to upregulation of indoleamine 2,3-dioxygenase (IDO) expression and fostering regulatory T cell differentiation. This dual mechanism enables both angiogenesis inhibition and immune modulation, broadening its experimental utility (methodological update).

Evidence & Benchmarks

• SU5416 suppresses VEGF-induced proliferation in HUVECs with an IC50 of 0.04 ± 0.02 μM, confirming high potency (APExBIO, product page).
• In vivo, daily intraperitoneal administration of 1–25 mg/kg SU5416 significantly inhibits tumor growth in mouse xenograft models with no observed mortality at higher doses (Lemay et al., 2025).
• SU5416 blocks VEGFR2 phosphorylation and downstream ERK/MAPK activation in endothelial cells (internal evidence).
• SU5416 acts as an AHR agonist, inducing IDO and promoting regulatory T cell differentiation, relevant for immune modulation studies (AHR reference).
• Preclinical PAH models show that VEGFR2 inhibition by SU5416, particularly in combination with hypoxia, triggers pulmonary vascular remodeling, modeling disease progression (Lemay et al., 2025).
• SU5416 is insoluble in water/ethanol but achieves ≥11.9 mg/mL solubility in DMSO; warming or sonication enhances dissolution (formulation data).

Applications, Limits & Misconceptions

SU5416 (Semaxanib) is deployed in diverse research fields:

• Cancer research: Inhibits tumor angiogenesis and vascularization, supporting studies on solid tumor growth and metastasis (additional benchmarks). This article extends previous summaries by detailing immune modulation and translational workflow parameters.
• Vascular disease models: Used to induce pulmonary hypertension in animal models when combined with hypoxic exposure, recapitulating human PAH features (Lemay et al., 2025).
• Immunology research: Exploits AHR agonist activity to study IDO induction and regulatory T cell differentiation, with implications for autoimmunity and transplant tolerance (see update).
• Translational studies: Serves as a tool for dissecting angiogenic and immune pathways, benchmarking new therapeutic strategies. Extends content from Translational Frontiers in Angiogenesis and Immune Modulation by providing atomic, unit-specific protocol data.

Common Pitfalls or Misconceptions

• SU5416 is not effective against angiogenesis driven by VEGFR1 or non-VEGF receptor pathways.
• It does not dissolve in water or ethanol; improper solubilization may result in precipitation or loss of activity.
• High doses in non-murine models may require additional toxicity evaluation, as most safety data derive from murine studies.
• SU5416's immune effects are AHR-dependent and may not generalize to all immunomodulatory contexts.
• It is not a curative therapy for cancer or PAH but a research tool for modeling and mechanistic studies.

Workflow Integration & Parameters

APExBIO supplies SU5416 (A3847) as a stable, research-grade inhibitor. Key workflow considerations include:

• Stock Preparation: Dissolve in DMSO to ≥11.9 mg/mL. Warming to 37°C or brief sonication increases dissolution rate (APExBIO A3847).
• Storage: Aliquots are stable at -20°C for several months; repeated freeze-thaw cycles should be avoided.
• In vitro use: Typical concentrations range from 0.01–100 μM. Validate with appropriate vehicle controls.
• In vivo protocols: Administer 1–25 mg/kg intraperitoneally in mouse models. Monitor for signs of toxicity at higher doses.
• Data reporting: Always include solvent, concentration, administration route, and animal/plate details for reproducibility.

For troubleshooting and workflow optimization, see this methodological review, which SU5416's workflow integration and troubleshooting strategies.

Conclusion & Outlook

SU5416 (Semaxanib) remains a gold-standard selective VEGFR2 tyrosine kinase inhibitor for angiogenesis and immune modulation research. Its validated potency, dual mechanism of action, and robust preclinical profile enable applications in oncology, vascular biology, and immunology. APExBIO's standardized SU5416 (A3847) supports reproducible experimental design. Future research may further leverage its dual activity for combined anti-angiogenic and immunotherapeutic strategies.

For more protocol details and product specifications, refer to the official SU5416 (Semaxanib) VEGFR2 inhibitor product page.